Berkeley Heights biopharma company names CEO

CorMedix has appointed Joseph Todisco to lead it

Pipette with drop of color liquid and petri dishes

Biopharmaceutical company CorMedix Inc. has appointed Joseph Todisco as its CEO, according to a Thursday announcement from the Berkeley Heights firm.

Todisco is expected join CorMedix on May 16 or earlier, as he completes his contractual responsibilities to his current employer.

“We are delighted to welcome Joe to CorMedix as the new chief executive officer. Having built pharmaceutical businesses in the past and led successful commercial organizations globally, Joe brings significant and relevant experience to the company,” Myron Kaplan, chairman of CorMedix’s board of directors, stated.

CorMedix recently resubmitted its DefenCath NDA to the Food & Drug Administration. The investigational drug product, is a novel antibacterial and antifungal solution being developed for the prevention of catheter-related bloodstream infections. The company’s team has been active on all fronts as it has worked through manufacturing challenges and continued to build its understanding of the commercial opportunity for DefenCath.

The board said it believes Todisco is the right person to lead CorMedix as it continues to advance DefenCath and aims to build a successful commercial franchise around its lead product.

“CorMedix has a strong late-stage pre-commercial asset in DefenCath, with a compelling value proposition for patients in the hemodialysis community,” Todisco said. “I am excited to be taking on this role, and I look forward to working alongside the CorMedix board, management and employees to continue building the company as we prepare for a potential commercial launch in hemodialysis and explore new opportunities for growth.”

Todisco is an experienced pharmaceutical industry leader with a track record of building businesses globally and providing commercial leadership over the last 20 years. Previously, Todisco was a senior executive at Amneal Pharmaceuticals, where, for the past 11 years, he has held various roles, most recently as executive vice president, chief commercial officer, where he was responsible for Amneal Specialty, a growing branded products business with $380 million in revenue and approximately 200 employees.